Edgewise Therapeutics, Inc.
EWTX
$34.15
-$0.69-1.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -176.01M | -167.80M | -157.24M | -150.70M | -146.09M |
| Total Depreciation and Amortization | 2.30M | 2.27M | 2.32M | 2.35M | 2.32M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.65M | 27.09M | 23.83M | 21.44M | 17.58M |
| Change in Net Operating Assets | -2.44M | -5.37M | -1.09M | 2.13M | 7.89M |
| Cash from Operations | -148.49M | -143.82M | -132.18M | -124.78M | -118.30M |
| Capital Expenditure | -472.00K | -256.00K | -457.00K | -888.00K | -1.06M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -73.78M | -32.53M | -61.17M | -71.10M | 128.61M |
| Cash from Investing | -74.26M | -32.79M | -61.63M | -71.98M | 127.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 206.00M | 196.09M | 195.01M | 196.90M | 10.70M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 38.00K | 0.00 | 0.00 | -214.00K | -300.00K |
| Cash from Financing | 206.04M | 196.09M | 195.01M | 196.68M | 10.40M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.71M | 19.48M | 1.20M | -81.00K | 19.66M |